Johnson & Johnson (JNJ)

$239.98 +2.02 (0.85%)
Market Cap 574.36B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.34
Forward PE 20.91
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 7,612,184
Avg Vol 8,331,798
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 31%
Beta 0.34
Analysts Strong Sell
Price Target $243.76

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Deeznutsswapmeet
Deeznutsswapmeet Apr. 14 at 6:44 PM
$JNJ $KVUE $SPX $SPY @Suite510 is a complete moron. He’s been spamming about legal issues since $150. Dipshit has zero investment knowledge.
1 · Reply
yellowstar16
yellowstar16 Apr. 14 at 6:21 PM
$JNJ Large positions here . Happy with another Divy increase and YTD performance. Holding Long.
0 · Reply
HydrogenH2
HydrogenH2 Apr. 14 at 5:58 PM
$JNJ Here why...
0 · Reply
Pearl_Power
Pearl_Power Apr. 14 at 5:44 PM
$JNJ might be time $XLV
0 · Reply
HydrogenH2
HydrogenH2 Apr. 14 at 5:43 PM
$JNJ I'm taking some more profits... bring some $$$ to Telcos a little !!
0 · Reply
maikl_211
maikl_211 Apr. 14 at 5:04 PM
$ORCL $XOM $JNJ $ASML $MA
0 · Reply
Smikell9
Smikell9 Apr. 14 at 4:47 PM
$JNJ
0 · Reply
trenddetector
trenddetector Apr. 14 at 2:47 PM
$JNJ LOST IN A CANCER DIAGNOSIS? You don’t have to be a doctor to understand your treatment options. Your Cancer Path is a free, local-born resource that translates complex medical jargon into plain English. Find every FDA-approved treatment. Search live clinical trials (updated daily). Follow a step-by-step diagnostic guide. 100% Free. 100% Anonymous. No account needed. Start your path at: www.yourcancerpath.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 1:59 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $240.00 | Type: CALL Option Plan (premium): Entry: $3.25 Stop: $2.34 TP1: $4.23 TP2: $5.52 TP3: $7.80 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
Skimman
Skimman Apr. 14 at 1:43 PM
$JNJ Company killing it.. stock does this shit
1 · Reply
Latest News on JNJ
Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 5 hours ago

Johnson & Johnson CFO on the company's robotic surgical system

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Apr 14, 2026, 10:30 AM EDT - 5 hours ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 9 hours ago

J&J raises guidance for 2026 on strong start to the year

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:25 AM EDT - 9 hours ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:21 AM EDT - 9 hours ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 9 hours ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 9 hours ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

Apr 13, 2026, 11:36 AM EDT - 1 day ago

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

Apr 12, 2026, 2:00 PM EDT - 2 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 10, 2026, 8:00 AM EDT - 4 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 9, 2026, 7:57 AM EDT - 5 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 8, 2026, 10:41 AM EDT - 6 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Apr 7, 2026, 8:00 AM EDT - 7 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 15 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 AM EDT - 17 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 4:46 PM EDT - 17 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 27, 2026, 6:31 AM EDT - 18 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 26 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 19, 2026, 9:35 AM EDT - 26 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 27 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 1:17 PM EDT - 27 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 27 days ago

US FDA approves J&J's oral psoriasis pill

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 7:49 AM EDT - 27 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 16, 2026, 11:00 AM EDT - 4 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 13, 2026, 12:35 PM EDT - 4 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 12, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 3:55 PM EST - 5 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 5 weeks ago

US FDA approves JNJ's blood cancer drug

Johnson & Johnson launches website for direct-to-consumer sales

Mar 4, 2026, 6:07 PM EST - 5 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 3, 2026, 8:03 AM EST - 6 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 2, 2026, 4:30 PM EST - 6 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 2:30 PM EST - 6 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 4:03 PM EST - 6 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 7 weeks ago

Does JNJ Stock Still Offer Value?

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 7 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 23, 2026, 10:28 AM EST - 7 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 21, 2026, 8:00 AM EST - 7 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 5:00 PM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:34 PM EST - 7 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 2:11 PM EST - 7 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:44 AM EST - 7 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:17 AM EST - 7 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 10:15 AM EST - 7 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 18, 2026, 7:30 AM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 8:00 AM EST - 2 months ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:19 PM EST - 2 months ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 4:18 PM EST - 2 months ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 2:43 PM EST - 2 months ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 13, 2026, 7:00 AM EST - 2 months ago

After A 55% Surge, Is JNJ Stock Still A Buy?

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 11, 2026, 2:23 PM EST - 2 months ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Deeznutsswapmeet
Deeznutsswapmeet Apr. 14 at 6:44 PM
$JNJ $KVUE $SPX $SPY @Suite510 is a complete moron. He’s been spamming about legal issues since $150. Dipshit has zero investment knowledge.
1 · Reply
yellowstar16
yellowstar16 Apr. 14 at 6:21 PM
$JNJ Large positions here . Happy with another Divy increase and YTD performance. Holding Long.
0 · Reply
HydrogenH2
HydrogenH2 Apr. 14 at 5:58 PM
$JNJ Here why...
0 · Reply
Pearl_Power
Pearl_Power Apr. 14 at 5:44 PM
$JNJ might be time $XLV
0 · Reply
HydrogenH2
HydrogenH2 Apr. 14 at 5:43 PM
$JNJ I'm taking some more profits... bring some $$$ to Telcos a little !!
0 · Reply
maikl_211
maikl_211 Apr. 14 at 5:04 PM
$ORCL $XOM $JNJ $ASML $MA
0 · Reply
Smikell9
Smikell9 Apr. 14 at 4:47 PM
$JNJ
0 · Reply
trenddetector
trenddetector Apr. 14 at 2:47 PM
$JNJ LOST IN A CANCER DIAGNOSIS? You don’t have to be a doctor to understand your treatment options. Your Cancer Path is a free, local-born resource that translates complex medical jargon into plain English. Find every FDA-approved treatment. Search live clinical trials (updated daily). Follow a step-by-step diagnostic guide. 100% Free. 100% Anonymous. No account needed. Start your path at: www.yourcancerpath.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 1:59 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $240.00 | Type: CALL Option Plan (premium): Entry: $3.25 Stop: $2.34 TP1: $4.23 TP2: $5.52 TP3: $7.80 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
Skimman
Skimman Apr. 14 at 1:43 PM
$JNJ Company killing it.. stock does this shit
1 · Reply
wwmeinc
wwmeinc Apr. 14 at 1:23 PM
$VKTX $LLY $NVO $JNJ $ABBV ......KLRA's S-1 released...looking for a $14-$16 IPO price but not set in stone yet...14 M shares maybe...or more...looks like they are planning on this upcoming Friday as a trading start...money coming to our sector.....helps in keeping our name on top to my eyes....but that is just my opinion...glta https://www.iposcoop.com/the-ipo-buzz-obesity-focused-kailera-therapeutics-sets-500-million-ipo/
1 · Reply
briefingcom
briefingcom Apr. 14 at 12:50 PM
$JNJ: Johnson & Johnson beat EPS expectations by $0.02, beat revenue expectations, raised its FY26 guidance, and increased its quarterly dividend by 3.1%
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 14 at 12:44 PM
$JNJ (-1.7% pre) Johnson & Johnson Earnings: JNJ Stock Slips on Modest 2026 Sales Forecast despite Q1 Beat https://ooc.bz/l/98698
0 · Reply
CHItraders
CHItraders Apr. 14 at 12:42 PM
$JNJ ohnson & Johnson reiterates 2026 is shaping up as a year of accelerated growth and impact
0 · Reply
AeroStrike_7348
AeroStrike_7348 Apr. 14 at 12:40 PM
$JNJ defensive flow steady not exciting but holding trend clean
0 · Reply
Skimman
Skimman Apr. 14 at 12:20 PM
$JNJ $KVUE $SPX $SPY just go away.. CC at 830.. nice try
0 · Reply
cmgventure
cmgventure Apr. 14 at 12:10 PM
$JNJ | Johnson & Johnson beat earnings and revenue estimates in Q1 and slightly raised its FY guidance. The stock is -1.0% this morning. 🔹 EPS: $2.70 vs. $2.68 est. ✅ 🔹 Revenue: $24.06B vs. $23.61B est. ✅ Key takeaways: 🔸 Innovative med revenue: +11% YoY 🔸 MedTech revenue: +8% YoY 🔸 US customer sales: +8% YoY 🔸 FY revenue outlook: ~$100.8B (~$100.5B prior) 🔸 FY EPS outlook: ~$11.55 (~$11.53 prior)
0 · Reply
Suite510
Suite510 Apr. 14 at 12:03 PM
$JNJ $KVUE $SPX $SPY lol 😂 litigation starting to bite 🧛‍♂️ “earnings and diluted EPS declined over 52%, impacted by significant restructuring expenses, litigation”
0 · Reply
Suite510
Suite510 Apr. 14 at 11:58 AM
$JNJ $KVUE $SPX $SPY WOW wonder how that court order mediatation went yesterday 🤣🥃🤓 Eventually they will lose 30B plus
0 · Reply
SenefAS
SenefAS Apr. 14 at 11:46 AM
$JNJ $GMAB Boommm $4B sales for Darzalex Q1 Genmab & Johnson… Tic tac 🙃
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 14 at 11:40 AM
$JNJ Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $2.14 down -53.17% YoY • Reported revenue of $24.06B up 9.91% YoY • Johnson & Johnson increases 2026 guidance with estimated reported sales of $100.8B or 7.0% at the midpoint, and adjusted EPS of $11.55 or 7.1% at the midpoint.
0 · Reply
maaar
maaar Apr. 14 at 11:09 AM
$JNJ why is this falling?
0 · Reply